Related Experiment Video
Updated: Jul 28, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast Cancer
Gary A Ulaner1, Amy M Fowler2, Amy S Clark3
1Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, CA, USA; Radiology and Translational Genomics, University of Southern California, Los Angeles, CA, USA.
Abstract:
Estrogen receptor (ER)-targeted imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES) has multiple proven clinical applications for patients with ER-positive breast cancer, including helping to select optimal patients for endocrine therapies, assessing ER status in lesions that are difficult to biopsy, and evaluating lesions with inconclusive results on other imaging tests. This has led to US Food and Drug Administration approval of 18F-FES PET for patients with ER-positive breast cancer. Newer progesterone receptor-targeted imaging agents are in clinical trials.
Insights
16α-18F-fluoro-17β-fluoroestradiol (18F-FES) PET imaging is FDA-approved for ER-positive breast cancer. It aids in treatment selection, biopsy assessment, and evaluating unclear lesions, improving patient care.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceuticals
Background:
- Estrogen receptor (ER)-positive breast cancer is a significant clinical challenge.
- Accurate assessment of ER status is crucial for guiding endocrine therapy decisions.
- Limitations exist in traditional methods for evaluating ER status in certain breast cancer lesions.
Purpose of the Study:
- To highlight the clinical utility of 16α-18F-fluoro-17β-fluoroestradiol (18F-FES) PET imaging in ER-positive breast cancer.
- To underscore the FDA approval and established applications of 18F-FES PET.
- To briefly mention emerging imaging agents targeting progesterone receptors.
Main Methods:
- Utilizing 18F-FES as a positron emission tomography (PET) tracer targeting estrogen receptors.
- Clinical application in patients with ER-positive breast cancer.
- Evaluation of lesions with inconclusive imaging or biopsy results.
Main Results:
- 18F-FES PET has demonstrated multiple proven clinical applications for ER-positive breast cancer.
- It assists in selecting patients for endocrine therapies.
- It is valuable for assessing ER status in difficult-to-biopsy lesions and evaluating inconclusive imaging findings.
Conclusions:
- 18F-FES PET imaging is an approved and valuable tool for managing ER-positive breast cancer.
- Its applications include guiding therapy selection and improving diagnostic accuracy for challenging cases.
- Ongoing research is exploring new receptor-targeted imaging agents.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...